Dishman Carbogen Amcis’ arm enters into co- investment agreement with European customers

25 Aug 2021 Evaluate

Dishman Carbogen Amcis’ wholly owned subsidiary -- Carbogen Amcis AG has entered into co- investment agreement with one of its key European customers. The agreement provides for additional process capabilities and capacities to facilitate the manufacture of the customer’s commercial product and follows a previous investment of Swiss franc 6 million.

The co-investment totals Swiss franc 4 million and will be focussed on expanding capacities to support the market introduction of the customer’s lead compound. The investment at the Carbogen Amcis AG. Neuland location includes the addition of a medium pressure chromatography column (200L), a preparative 20 cm HPLC system and short path distillation equipment.

Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.

Dishman Carbogen Amc Share Price

202.60 3.05 (1.53%)
14-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1545.25
Dr. Reddys Lab 5861.00
Cipla 1356.95
Zydus Lifesciences 984.75
Lupin 1635.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.